The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Campos-Toimil M, García-Caballero T, Barral L, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González-Juanatey JR, Feijóo-Bandín S, Lago F.
Aragón-Herrera A, et al. Among authors: lago f.
Front Pharmacol. 2022 Feb 2;13:827033. doi: 10.3389/fphar.2022.827033. eCollection 2022.
Front Pharmacol. 2022.
PMID: 35185578
Free PMC article.